Metformin activates AMP-activated protein kinase by promoting formation of the αβγ heterotrimeric complex

Area of Science:

• Molecular Biology
• Cellular Metabolism
• Endocrinology

Background:

• Metformin is a primary oral anti-diabetic medication.
• Low metformin concentrations activate AMP-activated protein kinase (AMPK) in hepatocytes, suppressing glucose production.
• The precise mechanism of metformin-induced AMPK activation, specifically increased AMPKα phosphorylation at Thr-172, remains unclear.

Purpose of the Study:

• To elucidate the molecular mechanism by which low metformin concentrations increase AMPKα phosphorylation at Thr-172.
• To investigate how metformin influences the formation and activity of the AMPK complex in hepatocytes.

Main Methods:

• Investigated the effect of low metformin concentrations on AMPK complex formation (AMPK αβγ).
• Assessed metformin's impact on the phosphorylation status of AMPKα at Thr-172.
• Examined the roles of LKB1 (kinase) and PP2C (phosphatase) in metformin-induced AMPK phosphorylation.

Main Results:

• Low metformin concentrations promote the assembly of the AMPK αβγ complex.
• Metformin enhances net phosphorylation of AMPKα at Thr-172.
• This effect is mediated by increased phosphorylation by LKB1 and decreased dephosphorylation by PP2C.

Conclusions:

• Low-dose metformin activates AMPK by facilitating AMPK αβγ complex formation.
• This complex formation enhances AMPKα Thr-172 phosphorylation via LKB1, while inhibiting PP2C-mediated dephosphorylation.
• The findings reveal a novel mechanism for metformin's glucose-lowering effects at the molecular level.